3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1
1
Status
Active not recruiting
3
Unknown
1
Recruiting
1
Completed
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
3
Sponsor
Cancer Type
Breast
3
Conditions
Ovarian Neoplasms
8
Breast Neoplasms
6
Prostatic Neoplasms
5
Triple Negative Breast Neoplasms
3
Neoplasms
3
Neoplasm Metastasis
3
Fallopian Tube Neoplasms
3
Small Cell Lung Carcinoma
2
Prostatic Neoplasms, Castration-Resistant
2
Lung Neoplasms
2
Glioma
2
Glioblastoma
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Sarcoma
1
Recurrence
1
Pancreatic Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasm, Residual
1
Mouth Neoplasms
1
Metastatic Castration-sensitive Prostate Cancer
1
Laryngeal Diseases
1
Hereditary Sensory and Autonomic Neuropathies
1
Endometrial Neoplasms
1
Disease Progression
1
Colorectal Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Ovarian Epithelial
1
Interventions
Carboplatin
25
Paclitaxel
24
pembrolizumab
22
Cyclophosphamide
14
Gemcitabine
10
Capecitabine
10
Doxorubicin
9
Specimen Handling
8
Nivolumab
8
Taxes
7
Magnetic Resonance Spectroscopy
7
sacituzumab govitecan
6
olaparib
6
Cisplatin
6
eribulin
5
durvalumab
5
atezolizumab
5
Radiotherapy
5
Albumin-Bound Paclitaxel
5
130-nm albumin-bound paclitaxel
5
capivasertib
4
Epirubicin
4
Docetaxel
4
Biopsy
4
niraparib
3
Vinorelbine
3
Radiation
3
Fulvestrant
3
Blood Specimen Collection
3
trastuzumab deruxtecan
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Active not recruiting
×
Triple Negative Breast Neoplasms
×
niraparib
×
Clear all
NCT04837209
2025-10-01
NADiR
Massachusetts General Hospital
Phase 2
Active not recruiting
32 enrolled
NCT03945721
2025-09-29
UNITY
Massachusetts General Hospital
Phase 1
Active not recruiting
21 enrolled
NCT04915755
2025-07-16
ZEST
GlaxoSmithKline
Phase 3
Active not recruiting
40 enrolled
13 charts